CHEVRON AND HIV THE CONSPIRACY (AFRICA IS ALWAYS THE TARGET)

The Oil company Chevron also owns a patent to for HIV-medications
Functionalized higher diamondoids
Assignee Chevron U.S.A. Inc.
Patent 7795468 Issued on September 14, 2010. Estimated Expiration Date: December 6, 2022.
As set forth above the functionalized higher diamondoids of the present invention are expected to be useful in the treatment of viral infections, in particular HIV, as well as chemical intermediates and as materials of construction.
The present invention preferably provides a method of treatment of viral infections, in particular HIV,

Positive-strand RNA viruses include Retroviridae such as the viruses causing human T-cell leukemia (HTLV-I and HTLV-II) and Acquired Immunodeficiency Disease (AIDS) (HIV-1 and HIV-2). The HIV viruses have many characteristics of lentiviruses.
To measure the ability of higher diamondoids to inhibit viral infections, anti-HIVassays and virus neutralization assays may be utilized. Anti-HIV assays and virus neutralization assays are well known to those of skill in the art.
The MT-2 cell line can be successfully used as targets for HIV-1 infection and requires only 4 to 5 days for complete cytopathic effect (CPE).

About Unknown

This is a short description in the author block about the author. You edit it by entering text in the "Biographical Info" field in the user admin panel.